Pharmaceutical News

RSS

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application (BLA) for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

2 Dec 2013

Shire signs agreement to supply authorized generic version of Adderall XR

Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR.

2 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Pharmaceutical industry in Asia to experience intensified competition

As Asia emerges as a major engine of global economic growth, the pharmaceutical and biotechnology industries in the region are expected to experience intensified competition. According to the Economist Intelligence Unit, regional pharmaceutical sales are expected to hit USD386bn, reflecting an annual average growth rate of more than 13%.

2 Dec 2013

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Cell Therapeutics, Inc. today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOX (arsenic trioxide).

2 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

American scientists introduce novel gel for sealing wounds

In first-aid situations, wounds must be quickly and effectively closed to stop blood loss and prevent infection. For treatment on arrival in a hospital, the temporary seal must be reopened, which often causes additional damage to the injured tissue. In the journal Angewandte Chemie, American scientists have now introduced a novel gel for sealing wounds. The gel can later be dissolved and gently removed.

28 Nov 2013

Modafinil in combination with antidepressants reduces severity of depression more effectively

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

28 Nov 2013

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so far.

27 Nov 2013

Nonabsorbable antibiotics effective in eradicating CRE colonization

Orally administered, nonabsorbable antibiotics were effective in eradicating carbapenem-resistant Enterobacteriaceae (CRE) colonization, according to a new study published in the December issue of the American Journal of Infection Control, a publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

27 Nov 2013

Multivitamin supplements can reduce incidence of pre-eclampsia

Pre-eclampsia is a serious complication of pregnancy that currently affects 6-8% of all pregnancies in Australia. Griffith Health Institute researchers have recently found that multivitamin supplements, including those that contain selenium, can reduce the incidence of PE, especially for overweight mothers.

27 Nov 2013

Typhoon survivors in Tacloban vaccinated against measles and polio

Children in Tacloban – the city hit hardest by Typhoon Haiyan – were vaccinated against measles and polio in the first phase of a mass campaign by the Government of the Philippines with support from UNICEF, the World Health Organization, and other partners. They also received Vitamin A supplements to help improve their immunity against infections.

27 Nov 2013

Drug interactions impact use of cholesterol-lowering statin drugs

A new study has found that many people who stopped taking cholesterol-lowering statin drugs were also taking an average of three other drugs that interfered with the normal metabolism of the statins.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

27 Nov 2013

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.

27 Nov 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

Study shows dl-3n-butylphthalide may have protective effects against diffuse brain injury

Dl-3n-butylphthalide can effectively treat cerebral ischemia; however, the mechanisms underlying the effects of dl-3n-butylphthalide on microcirculation disorders following diffuse brain injury remain unclear.

27 Nov 2013

HPV vaccine coverage among teens still remains low than other recommended vaccinations

Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication.

26 Nov 2013

Pharmaceutical News

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Shire signs agreement to supply authorized generic version of Adderall XR

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Pharmaceutical industry in Asia to experience intensified competition

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

American scientists introduce novel gel for sealing wounds

Modafinil in combination with antidepressants reduces severity of depression more effectively

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Nonabsorbable antibiotics effective in eradicating CRE colonization

Multivitamin supplements can reduce incidence of pre-eclampsia

Typhoon survivors in Tacloban vaccinated against measles and polio

Drug interactions impact use of cholesterol-lowering statin drugs

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

EU-funded project develops new type of vaccine to tackle HIV virus infection

Study shows dl-3n-butylphthalide may have protective effects against diffuse brain injury

HPV vaccine coverage among teens still remains low than other recommended vaccinations

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News